Loading…
OKYO Pharma Limited is projected to rise to $2.24 by 2027, a +35% move from its current price of $1.66. OKYO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.62 | $1.66 | $1.70 | +0.07% |
| Jul 13 | $1.60 | $1.66 | $1.72 | +0.15% |
| Jul 14 | $1.59 | $1.66 | $1.74 | +0.22% |
| Jul 15 | $1.58 | $1.66 | $1.75 | +0.29% |
| Jul 16 | $1.57 | $1.67 | $1.77 | +0.36% |
| Jul 17 | $1.56 | $1.67 | $1.78 | +0.44% |
| Jul 18 | $1.56 | $1.67 | $1.79 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.56 | $1.67 | $1.79 | +0.51% |
| Week 2 | $1.52 | $1.68 | $1.85 | +1.02% |
| Week 3 | $1.50 | $1.69 | $1.90 | +1.53% |
| Week 4 | $1.48 | $1.69 | $1.94 | +2.05% |
| Week 5 | $1.46 | $1.70 | $1.99 | +2.57% |
| Week 6 | $1.45 | $1.71 | $2.03 | +3.09% |
| Week 7 | $1.43 | $1.72 | $2.06 | +3.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease and in Phase II to treat neuropathic corneal pain; it is in preclinical trials to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment of acute and chronic ocular pain.
OKYO was incorporated in 2007 and is headquartered in London.
OKYO operates in the Healthcare sector, pursuing therapies for eye-related inflammatory conditions and pain. The description reflects a clinical-stage development focus with multiple programs across stages of research and development in the United Kingdom.
OKYO Pharma Limited (OKYO) currently trades at $1.75 per share and has a market capitalization of $91.84M. It is ranked 4270 by market capitalization.
The forecast outlook suggests upside from the current level, with the average price expected to rise to $3.15 by 2030 and to about $16.33 on average by 2050. Those long-run projections imply meaningful appreciation from the present price, with projected ROIs of 80% by 2030 and 833.2% by 2050, among bullish sentiment notes for later years.
In the nearer term, the forecast path envisions continued upside as the pipeline advances, with early years anchoring around a neutral stance before rising into the bullish outlook in the 2030s and beyond.
A major floor 16.7% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
The nearest ceiling, 5.4% above — a clean break opens room to run.
A major ceiling 14.7% above — clearing it would confirm fresh momentum.
Key OKYO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OKYO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.68 | Sell | $1.66 | Sell |
| MA 10 | $1.60 | Buy | $1.63 | Buy |
| MA 20 | $1.58 | Buy | $1.61 | Buy |
| MA 50 | $1.61 | Buy | $1.61 | Buy |
| MA 100 | $1.62 | Buy | $1.69 | Sell |
| MA 200 | $1.90 | Sell | $1.79 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.78 | Neutral |
| Stoch RSI (14) | 70.42 | Neutral |
| CCI (20) | 143.94 | Buy |
| Williams %R (14) | -24.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 6.96 | Buy |
| Bollinger %B (20,2) | 0.92 | Neutral |
| Stochastic %K (14) | 76.00 | Neutral |
| TRIX (15) | -0.05 | Sell |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 67.34 | Neutral |
| Momentum (10) | 0.15 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 1.73 | Sell |
| ADX (14) | 13.56 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is bullish, with RSI(14) at 70.
Near-term levels place resistance at $1.75 and support at $1.49, with the 50-day simple moving average at $1.60 and the 200-day simple moving average at $1.91. The stock’s 30-day price range spans from $1.47 to $2.08, and annualized volatility is around 50%.
Overall, price action has shown resilience within a tight range, with upside potential suggested by the current bullish sentiment and the proximity to the near-term resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.49 | $1.66 | $2.43 | 0% | Neutral | |
| $1.79 | $2.24 | $2.96 | +35% | Bullish | |
| $1.98 | $2.54 | $3.47 | +53% | Bullish | |
| $2.02 | $2.65 | $3.73 | +60% | Bullish | |
| $2.13 | $2.85 | $4.11 | +72% | Bullish | |
| $2.32 | $3.16 | $4.65 | +91% | Bullish | |
| $2.53 | $3.51 | $5.25 | +111% | Bullish | |
| $3.18 | $4.46 | $6.79 | +169% | Bullish | |
| $3.45 | $4.92 | $7.61 | +197% | Bullish | |
| $3.25 | $4.69 | $7.36 | +183% | Bullish | |
| $4.99 | $7.67 | $12.77 | +362% | Bullish | |
| $7.95 | $13.63 | $24.74 | +721% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.49 | $1.66 | $2.01 | +0.00% |
| August 2026 | $1.44 | $1.70 | $2.06 | +2.44% |
| September 2026 | $1.49 | $1.77 | $2.17 | +4.29% |
| October 2026 | $1.59 | $1.89 | $2.33 | +6.69% |
| November 2026 | $1.61 | $1.93 | $2.40 | +2.04% |
| December 2026 | $1.61 | $1.94 | $2.43 | +0.42% |
Click any year to see its month-by-month OKYO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The OKYO price prediction for 2026 points to an average of $1.66 (low $1.49, high $2.43) — a potential gain of 0% on today's $1.66. A consolidation phase looks the most probable path here.
In 2027, OKYO is projected to trade between $1.79 and $2.96, averaging $2.24 — a potential gain of +35% from today's $1.66. That is up +35% on the projected 2026 average. Momentum favours further upside here.
OKYO Pharma Limited's 2028 outlook centres on $2.54, within a $1.98 to $3.47 range. That is up +13% on the projected 2027 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, OKYO could reach as high as $3.73, with a base case around $2.65 and support toward $2.02 — roughly +60% from $1.66. Momentum favours further upside here.
Expect OKYO to range from $2.13 to $4.11 through 2030. The $2.85 average target implies a +72% move from current prices. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The OKYO price prediction for 2031 points to an average of $3.16 (low $2.32, high $4.65) — a potential gain of +91% on today's $1.66. Momentum favours further upside here.
In 2032, OKYO is projected to trade between $2.53 and $5.25, averaging $3.51 — a potential gain of +111% from today's $1.66. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
OKYO Pharma Limited's 2033 outlook centres on $4.46, within a $3.18 to $6.79 range. That is up +27% on the projected 2032 average. That marks a +169% change versus current levels. Momentum favours further upside here.
By 2034, OKYO could reach as high as $7.61, with a base case around $4.92 and support toward $3.45 — roughly +197% from $1.66. Buyers look set to stay in control over this stretch.
Expect OKYO to range from $3.25 to $7.36 through 2035. The $4.69 average target implies a +183% move from current prices. That is -5% versus the projected 2034 average. Momentum favours further upside here.
The OKYO price prediction for 2040 points to an average of $7.67 (low $4.99, high $12.77) — a potential gain of +362% on today's $1.66. Buyers look set to stay in control over this stretch.
In 2050, OKYO is projected to trade between $7.95 and $24.74, averaging $13.63 — a potential gain of +721% from today's $1.66. That is up +78% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in OKYO today (≈ 602.409639 OKYO) could be worth
$8,211.4
+$7,211.4 (+721%) by 2050 · US Dollar
Based on the average projected OKYO price of $13.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OKYOwould be worth at today's price.
$1,000 invested in OKYO on Jul 10, 2025 (≈ 349.650362 OKYO) would be worth
$580.42
-$419.58 (-42.0%) today · 0.58× · US Dollar
Based on a OKYO entry price of $2.86 vs. today's $1.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.57 | $1,057.32 | +5.7% |
| 1 month ago | $1.49 | $1,114.09 | +11.4% |
| 3 months ago | $1.51 | $1,099.34 | +9.9% |
| 6 months ago | $2.88 | $576.39 | -42.4% |
| 1 year ago | $2.86 | $580.42 | -42.0% |
| All time (4.2y) ago | $3.62 | $458.56 | -54.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OKYO forecast.
Our base-case forecast reaches $3.30 around 2032.
Implied market cap at $3.30: $173.18M
The multi-year forecast shows a clear upward trajectory across years, with notable milestones in the later horizon.
For 2026, the avg price is $1.75 with a min of $1.49 and a max of $2.58 and 0% ROI; 2027 forecasts an avg of $2.40 with a min of $1.92 and a max of $3.17 and a 37.2% ROI; 2028 shows an avg of $2.73 (min $2.13, max $3.74) with a 56.3% ROI; 2029 has an avg of $2.90 (min $2.21, max $4.08) and a 65.7% ROI, all with bullish sentiment toward the longer horizon.
The 2030 forecast stands at an avg of $3.15 (min $2.35, max $4.54) with an 80% ROI and a bullish sentiment. The 2040 projection shows an avg of $8.95 (min $5.81, max $14.91) and a 411.6% ROI, continuing the bullish view. By 2050, the avg price is projected at $16.33 (min $9.51, max $29.67) with an 833.2% ROI and a bullish stance.
These figures assume continued progress in the company’s ocular disease programs, including urcosimod and OK-201, and are subject to the uncertainties inherent in clinical-stage development, regulatory outcomes, and market dynamics. They are estimates, not guarantees, of future performance.
Tap a question to reveal the answer.
Avg price $3.15; min $2.35; max $4.54; ROI 80%; sentiment bullish.
Forecasts show bullish sentiment in later years, with 2050 avg $16.33 and ROI 833.2%; 2026 is neutral with avg $1.75 and ROI 0%. These are estimates, not guarantees.
Yes—forecast max price reaches $14.91 by 2040 and $29.67 by 2050, so $10 is within the modeled range.
Current price $1.75; market cap $91.84M; rank 4270.
Avg price $16.33; min $9.51; max $29.67; ROI 833.2%; sentiment bullish.
OKYO Pharma Limited Community Discussion
0Share your OKYO Pharma Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.